CEDRA Corporation Names CEO

CEDRA Corporation Names CEO
AUSTIN, Texas--(BUSINESS WIRE)--CEDRA Corporation, a division of Worldwide Clinical Trials (WCT) and a provider of Phase I clinical research and bioanalytical services, announced today that Anthony G. Busa, Jr., has been named Chief Executive Officer.

"He will be a great asset to our team in terms of growth and management."
.Busa has over 34 years of experience in management positions including senior level management, regional and national sales and product development within the pharmaceutical and medical device industries. His new position at CEDRA will utilize his core values and strategic vision developed throughout decades of experience.

"Anthony is an experienced, high caliber professional. He has a thorough understanding of how this business and industry functions," stated Worldwide Clinical Trials Chief Operating Officer, Tom Wardle. "He will be a great asset to our team in terms of growth and management."

Busa received his Bachelor of Science degree in biology from Iona College, located in New Rochelle, NY. He is a member of Drug Information Association (DIA), American Management Association (AMA) and Healthcare Manufacturer's Marketing Council, Inc. (HMMC).

Previously, Busa held senior management related positions at McClintic Busa Group, LLP, dgd Research, Inc., Esoterix, Inc., Medsites, Inc., and Covance, Inc.

About CEDRA
CEDRA Corporation, a division of Worldwide Clinical Trials, offers a full range of Phase I-IIb clinical research and bioanalytical services, as well as specialized studies to the pharmaceutical/biotech and medical device industries. CEDRA's combination of a state-of-the-art bioanalytical laboratory with clinical research sites allows them to play an important role in drug development programs. To learn more about CEDRA, visit www.cedracorp.com.


Contacts
SCORR Marketing
Kelly Sladek, 308-237-5567
[email protected]

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.